CA2940648A1 - Traitement des lesions resistantes - Google Patents

Traitement des lesions resistantes Download PDF

Info

Publication number
CA2940648A1
CA2940648A1 CA2940648A CA2940648A CA2940648A1 CA 2940648 A1 CA2940648 A1 CA 2940648A1 CA 2940648 A CA2940648 A CA 2940648A CA 2940648 A CA2940648 A CA 2940648A CA 2940648 A1 CA2940648 A1 CA 2940648A1
Authority
CA
Canada
Prior art keywords
connexin
lesion
subject
modulating agent
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2940648A
Other languages
English (en)
Inventor
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
Anthony Phillips
David Eisenbud (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocunexus Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of CA2940648A1 publication Critical patent/CA2940648A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes et des composition de modulation de protéine connexine permettant la cicatrisation de lésions résistantes, notamment de lésions chez des sujets atteints d'ulcères veineux multiples de la jambe ou d'ulcères du pied diabétique multiples, et chez d'autres sujets répondants. L'invention concerne également des kits et des articles manufacturés contenant un agent de modulation de protéine connexine, par exemple un agent de modulation de la connexine 43, destinés à être utilisés dans la cicatrisation des lésions résistantes.
CA2940648A 2014-02-25 2015-02-25 Traitement des lesions resistantes Abandoned CA2940648A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461944566P 2014-02-25 2014-02-25
US61/944,566 2014-02-25
PCT/US2015/017595 WO2015130840A2 (fr) 2014-02-25 2015-02-25 Traitement des lésions résistantes

Publications (1)

Publication Number Publication Date
CA2940648A1 true CA2940648A1 (fr) 2015-09-03

Family

ID=54009775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940648A Abandoned CA2940648A1 (fr) 2014-02-25 2015-02-25 Traitement des lesions resistantes

Country Status (3)

Country Link
EP (1) EP3110455A4 (fr)
CA (1) CA2940648A1 (fr)
WO (1) WO2015130840A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079406A1 (en) * 2018-04-10 2021-03-18 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
CN115103710A (zh) * 2019-09-30 2022-09-23 应用遗传科技公司 用于治疗遗传性听力损失的腺相关病毒(aav)系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2314321E (pt) * 1999-01-27 2014-09-26 Coda Therapeutics Inc Elemento de encaminhamento de um fluido de refrigeração de uma ferramenta de corte e processo para este encaminhamento
JP2011506447A (ja) * 2007-12-11 2011-03-03 コーダ セラピューティクス， インコーポレイテッド 損傷した創傷治癒組成物および治療
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments

Also Published As

Publication number Publication date
EP3110455A2 (fr) 2017-01-04
WO2015130840A2 (fr) 2015-09-03
EP3110455A4 (fr) 2017-10-11
WO2015130840A3 (fr) 2015-11-05

Similar Documents

Publication Publication Date Title
US20100279921A1 (en) Impaired wound healing compositions and treatments
RU2521329C2 (ru) Композиции и способы лечения плохо заживающих ран
US20110300130A1 (en) Impaired wound healing compositions and treatments
US20110038920A1 (en) Wound healing compositions and treatments
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
US20170056468A1 (en) Treatment of resistant lesions
WO2013148736A1 (fr) Compositions et traitements basés sur la modulation de la cadhérine
US20180028468A1 (en) Sustained release drug delivery devices
CA2940648A1 (fr) Traitement des lesions resistantes
US20160244759A1 (en) Compositions and treatments based on cadherin modulation
CA2941140A1 (fr) Traitement de lesions resistantes
EP2970978A1 (fr) Compositions et méthodes de ciblage de la n-acétylglucosamine transférase à liaison o et d'accélération de la cicatrisation des plaies
AU2017202281A1 (en) Impaired wound healing compositions and treatments

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831